Evaluation of Prenatal Hepatitis C Virus Prevalence Using Universal Screening, and Linkage to Care in a Real-World Setting in Ontario
Mia J. Biondi(York University), Jordan J. Feld(University Health Network), Camelia Capraru(Toronto Liver Centre), Kate D. Lynch(Royal Adelaide Hospital), Lee Goneau(Western University), Natalie Floriancic(Toronto Liver Centre), Andrew Mendlowitz(University Health Network), Robert Kozak(Sunnybrook Hospital), Alex Marchand‐Austin(Public Health Ontario), Bettina E. Hansen(Aarhus University), Genevieve Eastabrook(London Health Sciences Centre), Mark H. Yudin(Ontario Neurotrauma Foundation), Kirby Cronin(Toronto Public Health), Vanessa Tran(Toronto Public Health), Tony Mazzulli(Mount Sinai Hospital)
Cited by 2
Related Papers
The immediate psychological and occupational impact of the 2003 SARS outbreak in a teaching hospital.
|PubMed|2003|1.6k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
|New England Journal of Medicine|2014|907
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664